1 / 4

Acromegaly Treatment Market Trends, Outlook, and Opportunity Analysis, 2018 - 2026

Acromegaly is a rare disorder caused due to the excess production of growth hormone by the pituitary gland, affecting a patientu2019s physical appearance and internal organs.<br>

bisenraj
Download Presentation

Acromegaly Treatment Market Trends, Outlook, and Opportunity Analysis, 2018 - 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acromegaly Treatment Market Exposure to varied markets, Acromegaly Treatment Market Exposure to varied markets, capacity expansion & diversification key triggers Estimated By capacity expansion & diversification key triggers Estimated By Global Players Pfizer Inc., Novartis Pharma AG, Global Players Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline plc, Midatech Pharma PLC GlaxoSmithKline plc, Midatech Pharma PLC Acromegaly Acromegaly is a rare disorder caused due to the excess production of growth hormone by the pituitary gland, affecting a patient’s physical appearance and internal organs. It is usually caused by benign pituitary tumor (adenoma), however, in rare cases acromegaly symptoms can be observed due to ineffective control of growth hormone-secreting cells by hypothalamus. Abnormal enlargement of hands, arms, feet, legs, and head, and gradual changes in facial features such as eye-brow, lower jaw, and nose are visible symptoms of this disorder. Untreated acromegaly leads to serious and life threating complications such as cardiomyopathy and ventricular arrhythmia. Blood test to measure levels of growth hormones or insulin-like growth factor and imaging of tumors through MRI scan and CT scan are commonly used diagnostic approaches to detect acromegaly. Some medications are 90% effective in shrinking tumor, however, success rate of type of treatment varies based on age, health or medical history of patients. According to the American Society of Clinical Oncology (ASCO), 14,230 individuals of the U.S. were diagnosed with pituitary gland tumor in 2017, of which majority are benign tumor. Furthermore, in 2017, the National Organization for Rare Disorders estimated the prevalence rate of acromegaly as 50-70 person per million and 3 new cases occurs per million every year, which is expected to increase the demand for acromegaly treatment market. Download PDF Brochure Of This Research Report @ Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1477 https://www.coherentmarketinsights.com/insight/request-pdf/1477 Market Driver: Market Driver: New drugs in the market widens the choice of therapies for doctors and patients. In 2017, Midatech Pharma PLC submitted clinical trial application in human study of Q-Octreotide (MTD201) programme in cancer and acromegaly, and now it has received oral confirmation from Polish regulators for its approval in January 2018. Furthermore, Chiasma Inc’s new oral maintenance therapy for acromegaly treatment named Mycapssa, which has completed an international Phase 3 trial and further conducting an international Phase 3 clinical trial under a protocol accepted by the European Medicines Agency (EMA) for adult patients with acromegaly

  2. is also expected to boost growth of acromegaly treatment market over the forecast period. Expiration of drug patents during the forecast period can hamper the market temporarily. As acromegaly is a non-preventable disease, early detection of the disease will help to cure the disease symptoms. Increasing awareness to differentiate between acromegaly and other disorders like gigantism, Marfan syndrome, and Pachydermoperiostosis, and further detecting the symptoms and diagnosing it will help in propelling the acromegaly treatment market growth. For instance, Acromegaly Awareness Day was celebrated on November 1, 2017 for the first time by World Alliance of Pituitary Organization (WAPO) and Pituitary Network Association to increase awareness on diagnosing the symptoms of this disease without any delay. Some foundation provided financial assistance to medicare patients suffering with acromegaly. For instance, in December 2017, HealthWell Foundation launched a new fund scheme where it provided a fund of US$ 10,000 for a 12-month grant to acromegaly patients who have annual household incomes up to 400 percent of the federal poverty level. Such funding programs will provide financial ease to the patients suffering from acromegaly, which in turn will propel growth of acromegaly treatment market. In 2017, Crinetics Pharmaceuticals, Inc. was awarded Phase IIB Small Business Innovation Research (SBIR) grant of up to US$ 2.8 million from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) for the development of company’s orally-available, non-peptide somatostatin agonist drug candidate, CRN00808 that can be used for the treatment of acromegaly. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Acromegaly Treatment Market Research Objective and Assumption • Acromegaly Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Acromegaly Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Acromegaly Treatment Market, By Regions • Acromegaly Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Acromegaly Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Acromegaly Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials

  3. Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Acromegaly Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Acromegaly Treatment Market – Competitors: Acromegaly Treatment Market – Competitors: Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline plc, Midatech Pharma PLC, Strongbridge Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline plc, Midatech Pharma PLC, Strongbridge Biopharma plc, Chiasma Inc, Aegis Therapeutics LLC, Amryt Pharma plc, Antisense Therapeutics Biopharma plc, Chiasma Inc, Aegis Therapeutics LLC, Amryt Pharma plc, Antisense Therapeutics Ltd, Crinetics Pharmaceuticals Inc, Dauntless Pharmaceuticals Inc, and Ipsen Biopharmaceuticals Ltd, Crinetics Pharmaceuticals Inc, Dauntless Pharmaceuticals Inc, and Ipsen Biopharmaceuticals Inc. are the major players involved in acromegaly treatment market. Inc. are the major players involved in acromegaly treatment market. Browse Complete Report For More Information @ Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/acromegaly-treatment-market-1477 https://www.coherentmarketinsights.com/ongoing-insight/acromegaly-treatment-market-1477 Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click competition, and market potential. For more information or to access this database, kindly click on the below link or contact at on the below link or contact at sales@coherentmarketinsights.com sales@coherentmarketinsights.com https://www.coherentmarketinsights.com/phase-xs/ https://www.coherentmarketinsights.com/phase-xs/ About Coherent Market Insights: About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200

  4. Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com

More Related